Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 14/20 | 0.57 |
| ▸ | ACACB | O00763 | 3/20 | 0.39 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.37 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.37 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.37 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.36 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1637381 | 0.85 | P2RX7 (0.61) | P2RX7ACACBADRB1HCRTR1HCRTR2 | |
| SCHEMBL1636108 | 0.84 | P2RX7 (0.56) | P2RX7HCRTR1HCRTR2 | |
| SCHEMBL1636701 | 0.83 | P2RX7 (0.47) | P2RX7 | |
| SCHEMBL1635930 | 0.78 | P2RX7 (0.50) | P2RX7 | |
| SCHEMBL1637690 | 0.77 | P2RX7 (0.56) | P2RX7ACACB | |
| SCHEMBL1636761 | 0.74 | P2RX7 (0.51) | P2RX7 | |
| SCHEMBL1636732 | 0.74 | P2RX7 (0.45) | P2RX7 | |
| SCHEMBL1636796 | 0.74 | P2RX7 (0.45) | P2RX7 | |
| SCHEMBL14041470 | 0.73 | P2RX7 (0.68) | P2RX7 | |
| SCHEMBL1637705 | 0.73 | P2RX7 (0.53) | P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7932282-B2 | Imidazolidine carboxamide derivatives as P2X7 modulators | GLAXO GROUP LIMITED (GB) | 2011-04-26 | — | — | US | disclosed |
| US-20100075968-A1 | Imidazolidine Carboxamide Derivatives as P2X7 Modulators | GLAXO GROUP LIMITED (GB) | 2010-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100075968-A1 | Imidazolidine Carboxamide Derivatives as P2X7 Modulators | P2RX3, P2RX7, P2RX5 | P2RX7 2/4885ACACB 4178/4885ADRB1 272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.